Obesity - Pipeline Review, H1 2016

Obesity - Pipeline Review, H1 2016 is a new market research publication announced by Reportstack.This report provides comprehensive information on the therapeutics under development for Obesity, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Obesity and features dormant and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Complete report available @ Obesity - Pipeline Review, H1 2016

Scope

- The report provides a snapshot of the global therapeutic landscape of Obesity
- The report reviews pipeline therapeutics for Obesity by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Obesity therapeutics and enlists all their major and minor projects
- The report assesses Obesity therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Obesity

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Obesity
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Obesity pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Companies Mentioned

Abeome Corporation Advinus Therapeutics Ltd. Aegis Therapeutics, LLC Akron Molecules AG Alize Pharma SAS Amabiotics SAS Ambrx, Inc. Amgen Inc. Arena Pharmaceuticals, Inc. AstraZeneca Plc Asubio Pharma Co., Ltd. AtheroNova Inc. Athersys, Inc. Avaxia Biologics, Inc. BioLingus AG Biophytis SAS BioRestorative Therapies, Inc. BioTime, Inc. Boehringer Ingelheim GmbH Braasch Biotech LLC Bristol-Myers Squibb Company Camurus AB Carmot Therapeutics, Inc. Chronos Therapeutics Limited CohBar, Inc. CoMentis, Inc. Corium International, Inc. Daiichi Sankyo Company, Limited Diabetica Limited DiscoveryBiomed, Inc. Eisai Co., Ltd. Eli Lilly and Company Esperion Therapeutics, Inc. Eternygen GmbH Euroscreen S.A. F. Hoffmann-La Roche Ltd. FibroGen, Inc. Galenea Corp. GlaxoSmithKline Plc GTx, Inc. HanAll Biopharma Co., Ltd. Handok Inc. Hanmi Pharmaceuticals, Co. Ltd. Helsinn Healthcare S.A. Hyundai Pharmaceutical Co., Ltd. Immungenetics AG Intarcia Therapeutics, Inc. Ionis Pharmaceuticals, Inc. Jenrin Discovery, Inc. Johnson & Johnson Kissei Pharmaceutical Co., Ltd. Kowa Company, Ltd. Lead Discovery Center GmbH LEO Pharma A/S LG Life Science LTD. Magnus Life Science MAKScientific, LLC MedImmune, LLC Merck & Co., Inc. Mitochon Pharmaceuticals, Inc. Mitsubishi Tanabe Pharma Corporation Molecular Design International, Inc. NGM Biopharmaceuticals, Inc. Nimbus Therapeutics, LLC nLife Therapeutics, S.L. Nordic Bioscience A/S Novo Nordisk A/S ObeTherapy Biotechnology Omeros Corporation OPKO Health, Inc. Orbis Biosciences, Inc. Orexigen Therapeutics, Inc. Pfizer Inc. PharmaIN Corporation Progenra, Inc. Prometheon Pharma, LLC Reviva Pharmaceuticals Inc. Rhythm Pharmaceuticals, Inc. Saniona AB Sanofi Shanghai Pharmaceutical Co., Ltd. Shionogi & Co., Ltd. Sinil Pharmaceutical Co., Ltd Sirona Biochem Corp Sorrento Therapeutics, Inc. Sumitomo Dainippon Pharma Co., Ltd. Suven Life Sciences Ltd. Takeda Pharmaceutical Company Limited Toray Industries, Inc. Transition Therapeutics Inc. Umecrine AB Vicore Pharma AB Viking Therapeutics, Inc. WhanIn Pharmaceutical Co., Ltd. Xenetic Biosciences (UK) Limited XL-protein GmbH Zafgen Inc. Zealand Pharma A/S


Contact:
Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###